Cipla says FDA inspection at Invagen New York plant closed with no observations
Cipla reported that a USFDA inspection of its Invagen facility in New York, held October 19-22, 2026, ended with zero Form 483 observations.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
Indian drugmaker Cipla Ltd said the US Food and Drug Administration (USFDA) carried out an inspection at its Invagen facility in New York from October 19 to 22, 2026. The inspection concluded with zero Form 483 observations.
The information was reported by Reuters, based on the company's own statement.
why it matters
A clean Form 483 outcome generally indicates the plant meets the requirements of the US regulator. For Cipla shareholders this is a neutral to positive signal, since inspection problems can lead to shipment halts and pressure on revenue.
market impact
Cipla: a clean FDA result lowers regulatory risk for US supplies
tags
instruments
sources
- Cipla Says USFDA Conducts Inspection At Invagen Facility In New York — Reuters, 23 October 2026 at 03:33 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗